This study also provided in vivo experimental proof of the therapeutic concept that targeting MRP2 could sensitise MRP2-overexpressing human gastrointestinal tumours to the anti-tumour activity of oxaliplatin without increased toxicity. The gene discussed is ABCC2; the disease is digestive system neoplasm.